Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PTCT Ptc Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: PTCT
Price (delayed)
$46.01
Market cap
$3.65B
P/E Ratio
6.09
Dividend/share
N/A
EPS
$7.56
Enterprise value
$2.56B
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally
Highlights
The EPS has soared by 198% year-on-year
PTCT's gross profit has soared by 129% QoQ and by 99% YoY
Key stats
What are the main financial stats of PTCT
Market
Valuations
Earnings
Shares outstanding
79.26M
Market cap
$3.65B
Enterprise value
$2.56B
Price to earnings (P/E)
6.09
Price to book (P/B)
N/A
Price to sales (P/S)
2.03
EV/EBIT
3.15
EV/EBITDA
3.02
EV/Sales
1.44
Revenue
$1.77B
Gross profit
$1.72B
Operating income
$707.93M
Net income
$594.84M
EBIT
$811.66M
EBITDA
$846.9M
Free cash flow
$871.14M
Per share
Balance sheet
Liquidity
EPS
$7.56
EPS diluted
$6.51
Free cash flow per share
$11.15
Book value per share
-$2.36
Revenue per share
$22.69
TBVPS
$31.42
Total assets
$2.66B
Total liabilities
$2.84B
Debt
$389.62M
Equity
-$185.76M
Working capital
$1.72B
Debt to equity
-2.1
Current ratio
3.89
Quick ratio
3.76
Net debt/EBITDA
-1.29
Margins
Efficiency
Dividend
EBITDA margin
47.8%
Gross margin
96.9%
Net margin
33.6%
Operating margin
39.9%
Return on assets
29.3%
Return on equity
N/A
Return on invested capital
123.5%
Return on capital employed
39.4%
Return on sales
45.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PTCT stock price
How has the Ptc Therapeutics stock price performed over time
Intraday
1.54%
1 week
4.02%
1 month
-0.86%
1 year
35.2%
YTD
1.93%
QTD
-9.71%
Financial performance
How have Ptc Therapeutics's revenue and profit performed over time
Revenue
$1.77B
Gross profit
$1.72B
Operating income
$707.93M
Net income
$594.84M
Gross margin
96.9%
Net margin
33.6%
The company's net margin has surged by 175% QoQ and by 154% YoY
PTCT's operating margin has surged by 174% year-on-year
PTCT's gross profit has soared by 129% QoQ and by 99% YoY
Ptc Therapeutics's revenue has soared by 120% from the previous quarter and by 91% YoY
Price vs fundamentals
How does PTCT's price correlate with its fundamentals
Growth
What is Ptc Therapeutics's growth rate over time
Valuation
What is Ptc Therapeutics stock price valuation
P/E
6.09
P/B
N/A
P/S
2.03
EV/EBIT
3.15
EV/EBITDA
3.02
EV/Sales
1.44
The EPS has soared by 198% year-on-year
Ptc Therapeutics's equity has surged by 83% QoQ and by 79% YoY
Ptc Therapeutics's revenue has soared by 120% from the previous quarter and by 91% YoY
The price to sales (P/S) is 59% lower than the 5-year quarterly average of 5.0 and 35% lower than the last 4 quarters average of 3.1
Efficiency
How efficient is Ptc Therapeutics business performance
The ROS has soared by 185% year-on-year
Ptc Therapeutics's ROA has soared by 179% YoY
Dividends
What is PTCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PTCT.
Financial health
How did Ptc Therapeutics financials performed over time
The total assets is 7% less than the total liabilities
The quick ratio has surged by 100% year-on-year and by 69% since the previous quarter
Ptc Therapeutics's current ratio has surged by 92% YoY and by 66% QoQ
Ptc Therapeutics's equity has surged by 83% QoQ and by 79% YoY
The company's debt fell by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.